GlassScriptPhysician profile
Keith Siller
NPI 1992714927
$11,538.76
in general payments reported to CMS, 2019-2025
27 companies · $267 in 2025
The $267 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,349 · 2020: $3,615 · 2021: $1,311 · 2022: $325 · 2023: $466 · 2024: $206 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $6,502.73 | 2019-2020 | |
| Eisai INC. | $1,494.36 | 2019-2021 | |
| Abbvie INC. | $713.45 | 2021-2025 | Qulipta, Ubrelvy |
| Alexion Pharmaceuticals, INC. | $476.21 | 2019-2021 | |
| Amgen INC. | $250.00 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $246.84 | 2025 | Rexulti |
| Allergan, INC. | $214.50 | 2020-2021 | |
| Sk Life Science, INC. | $205.11 | 2021 | |
| Chiesi USA, INC. | $196.28 | 2019-2024 | Elfabrio |
| Teva Pharmaceuticals USA, INC. | $188.59 | 2019-2020 | |
| Lundbeck LLC | $172.65 | 2019-2020 | |
| Ucb, INC. | $125.00 | 2019 | |
| Amneal Pharmaceuticals LLC | $124.09 | 2020 | |
| Impel Pharmaceuticals INC. | $113.06 | 2023 | Trudhesa |
| Medtronic, INC. | $100.22 | 2022-2023 | Percept PC Brainsense |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $75.45 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $55.68 | 2022 | |
| Grifols USA, LLC | $52.06 | 2019 | |
| Biogen, INC. | $40.90 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $36.94 | 2021 | |
| Boston Scientific Corporation | $31.04 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.86 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $23.65 | 2022 | |
| Lilly USA, LLC | $21.48 | 2022 | |
| Genentech USA, INC. | $20.64 | 2019 | |
| Akcea Therapeutics, INC. | $20.63 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Siller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.